2025
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Chen J, Levy A, Tian A, Huang X, Cai G, Fidelle M, Rauber C, Ly P, Pizzato E, Sitterle L, Piccinno G, Liu P, Durand S, Mao M, Zhao L, Iebba V, Felchle H, Mallard de La Varende A, Fischer J, Thomas S, Greten T, Jones J, Monge C, Demaria S, Formenti S, Belluomini L, Dionisi V, Massard C, Blanchard P, Robert C, Quevrin C, Lopes E, Clémenson C, Mondini M, Meziani L, Zhan Y, Zeng C, Cai Q, Morel D, Sun R, Laurent P, Mangoni M, Di Cataldo V, Arilli C, Trommer M, Wegen S, Neppl S, Riechelmann R, Camandaroba M, Neto E, Fournier P, Segata N, Holicek P, Galluzzi L, Buqué A, Alves Costa Silva C, Derosa L, Kroemer G, Chen C, Zitvogel L, Deutsch E. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 2025, 43: 361-379.e10. PMID: 40068595, PMCID: PMC11907695, DOI: 10.1016/j.ccell.2025.02.010.Peer-Reviewed Original ResearchConceptsPD-L1 blockadeLow-dose irradiationCancer patientsAbscopal effectEfficacy of PD-L1 blockadeCD8<sup>+</sup> T cell activationBenefit of immune checkpoint inhibitorsClinical benefit of immune checkpoint inhibitorsTumor-draining lymph nodesSecond-line immunotherapyImmune checkpoint inhibitorsPhase 2 studyProspective clinical trialTumor-bearing miceCohort of cancer patientsT cell activationMetastatic cancer patientsAnti-cancer efficacyCheckpoint inhibitorsLocal radiotherapyPD-L1Clinical benefitLymph nodesOptimal dosimetryRetrospective cohort
2024
Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response
Lin Y, Xie M, Lau H, Zeng R, Zhang R, Wang L, Li Q, Wang Y, Chen D, Jiang L, Damsky W, Yu J. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med 2024, 6: 100530. PMID: 39515321, DOI: 10.1016/j.medj.2024.10.007.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMicrobial biomarkersPredicting ICI responseGut microbiotaICI responseMulti-cancersEffects of gut microbiotaCheckpoint inhibitorsModulating CD8<sup>+</sup> T cells activityCD8<sup>+</sup> T cell activationICI respondersImmune checkpoint inhibitor recipientsPredictors of ICI responseImmune checkpoint inhibitor efficacyHungatella hathewayiCancer typesFecal metagenomesGut bacteriaSignature speciesT cell activationMicrobiota compositionF. prausnitziiPredicting therapeutic responseWilcoxon rank testMicrobiotaWnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis
Luan Y, Hu J, Wang Q, Wang X, Li W, Qu R, Yang C, Rajendran B, Zhou H, Liu P, Zhang N, Shi Y, Liu Y, Tang W, Lu J, Wu D. Wnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis. Cell Reports 2024, 43: 113934. PMID: 38461416, PMCID: PMC11064424, DOI: 10.1016/j.celrep.2024.113934.Peer-Reviewed Original ResearchCD8<sup>+</sup> T cell activationNeutrophil productionNeutrophil plasticitySplenic extramedullary myelopoiesisFamily member 5T cell activationInnate immune cellsSplenic stromal cellsDSS-Induced ColitisAnti-inflammatory protectionCD101 expressionPro-inflammatory activitySplenic myelopoiesisExtramedullary myelopoiesisBone marrowImmune cellsSplenic neutrophilsMember 5Autoimmune diseasesInflammatory outcomesCell activationStromal cellsColitisSplenic productionElevated numbers
2022
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-StimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute viruses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply